hotspot -WSS

hotspot

author：leisure time 2025-09-30 18:20:32 - browse：546

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

entertainment

WSS

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

New chief aims to remake Sanofi Genzyme

Secretariat’s lessons for human medicine

It's time to take a new tack for treating Alzheimer's

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

hotspot

hotspot

focus

Drug repurposing or repositioning? The language matters

It's time to take a new tack for treating Alzheimer's

Tori Bowie and the unacceptable rates of Black maternal death

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Affirmative action in medical school literally saved lives

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Novavax promises a turnaround & Lilly roils the obesity market

WATCH: Why do our ears pop?

Wikipedia

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Abridge raises $150m as clinical notes automation market heats up

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

entertainment

hotspot

entertainment

leisure time